NPRL3 Gene

NPRL3 Gene

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">NPRL3 Gene</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td>NPRL3</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>NPR3-Like (GATOR1 Complex Subunit)</td>
</tr>
<tr>
<td class="label">Aliases</td>
<td>HDRF1, FLJ14627</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>19q13.33</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>84450</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000177732</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td>Q9Y5Q3</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>617052</td>
</tr>
<tr>
<td class="label">Subunit</td>
<td>Role</td>
</tr>
<tr>
<td class="label">NPRL2</td>
<td>Scaffold</td>
</tr>
<tr>
<td class="label">NPRL3</td>
<td>Regulatory</td>
</tr>
<tr>
<td class="label">DEPDC5</td>
<td>Catalytic</td>
</tr>
<tr>
<td class="label">Protein</td>
<td>Interaction Type</td>
</tr>
<tr>
<td class="label">NPRL2</td>
<td>Direct binding</td>
</tr>
<tr>
<td class="label">DEPDC5</td>
<td>Subunit</td>
</tr>
<tr>
<td class="label">WDR24</td>
<td>GATOR2 component</td>
</tr>
<tr>
<td class="label">CASTOR1/2</td>
<td>GATOR2 component</td>
</tr>
<tr>
<td class="label">Strategy</td>
<td>Agent</td>
</tr>
<tr>
<td class="label">mTOR inhibition</td>
<td>Everolimus</td>
</tr>
<tr>
<td class="label">Ket

...

NPRL3 Gene

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">NPRL3 Gene</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td>NPRL3</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>NPR3-Like (GATOR1 Complex Subunit)</td>
</tr>
<tr>
<td class="label">Aliases</td>
<td>HDRF1, FLJ14627</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>19q13.33</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>84450</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000177732</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td>Q9Y5Q3</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>617052</td>
</tr>
<tr>
<td class="label">Subunit</td>
<td>Role</td>
</tr>
<tr>
<td class="label">NPRL2</td>
<td>Scaffold</td>
</tr>
<tr>
<td class="label">NPRL3</td>
<td>Regulatory</td>
</tr>
<tr>
<td class="label">DEPDC5</td>
<td>Catalytic</td>
</tr>
<tr>
<td class="label">Protein</td>
<td>Interaction Type</td>
</tr>
<tr>
<td class="label">NPRL2</td>
<td>Direct binding</td>
</tr>
<tr>
<td class="label">DEPDC5</td>
<td>Subunit</td>
</tr>
<tr>
<td class="label">WDR24</td>
<td>GATOR2 component</td>
</tr>
<tr>
<td class="label">CASTOR1/2</td>
<td>GATOR2 component</td>
</tr>
<tr>
<td class="label">Strategy</td>
<td>Agent</td>
</tr>
<tr>
<td class="label">mTOR inhibition</td>
<td>Everolimus</td>
</tr>
<tr>
<td class="label">Ketogenic diet</td>
<td>Metabolic</td>
</tr>
<tr>
<td class="label">ASD treatment</td>
<td>Multiple</td>
</tr>
<tr>
<td class="label">Subunit</td>
<td>Molecular Weight</td>
</tr>
<tr>
<td class="label">NPRL2</td>
<td>~46 kDa</td>
</tr>
<tr>
<td class="label">NPRL3</td>
<td>~46 kDa</td>
</tr>
<tr>
<td class="label">DEPDC5</td>
<td>~200 kDa</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Dose Range</td>
</tr>
<tr>
<td class="label">Everolimus</td>
<td>2.5-10 mg/day</td>
</tr>
<tr>
<td class="label">Sirolimus</td>
<td>1-4 mg/day</td>
</tr>
<tr>
<td class="label">Temsirolimus</td>
<td>Weekly IV</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/cancer" style="color:#ef9a9a">Cancer</a>, <a href="/wiki/tumor" style="color:#ef9a9a">Tumor</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">18 edges</a></td>
</tr>
</table>

Introduction

Nprl3 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

The NPRL3 gene (NPR3-Like, GATOR1 Complex Subunit) encodes a critical subunit of the GATOR1 complex, which serves as the primary negative regulator of mTORC1 signaling in response to amino acid deprivation^[1]. NPRL3 is essential for proper brain development and function, with pathogenic variants causing epilepsy and neurodevelopmental disorders. The gene is also implicated in various neurodegenerative diseases through its role in the [mTOR](/entities/mtor)-autophagy pathway^[2]. [@gator]

Gene Information

Protein Structure

NPRL3 is a 418-amino acid protein (approximately 46 kDa) with several structural features:

• Alpha-helical regions: Multiple predicted alpha-helices forming coiled-coil domains
• Protein-protein interaction domains: mediates interactions with NPRL2 and DEPDC5
• Disordered regions: Predicted intrinsically disordered regions that may undergo disorder-to-order transitions upon binding
• NPRL3 domain: A conserved domain unique to NPRL3 and related proteins^[3]

Molecular Function

GATOR1 Complex Component

NPRL3 functions as an essential component of the GATOR1 complex, which consists of three core subunits:

NPRL2 - The scaffolding protein

NPRL3 - Regulatory subunit

DEPDC5 - The catalytic subunit with GAP activity

Rag GTPase GAP Activity

The GATOR1 complex functions as a GTPase-activating protein (GAP) for the Rag GTPases (RagA/B and RagC/D). Under amino acid-poor conditions, GATOR1 promotes the inactive GDP-bound state of Rags, preventing mTORC1 recruitment to the lysosome^[1].

mTORC1 Inhibition

By inactivating Rag GTPases, NPRL3-containing GATOR1 complex:

• Prevents mTORC1 activation during amino acid starvation
• Promotes autophagy induction
• Inhibits protein synthesis
• Supports cellular stress responses

Brain Development Functions

During neural development, NPRL3 is critical for:

• Cortical neuron proliferation and differentiation
• Synapse formation and plasticity
• Axonal guidance
• Astrocyte function^[4]

Expression Pattern

NPRL3 exhibits a widespread expression pattern with highest levels in neural tissue:

Tissue Distribution

• Brain: Highest expression in cerebral [cortex](/brain-regions/cortex), [hippocampus](/brain-regions/hippocampus), and cerebellum
• Heart: Moderate expression
• Kidney: Moderate expression
• Lung: Lower expression
• Other tissues: Variable, generally low

Cellular Localization

In [neurons](/entities/neurons), NPRL3 localizes to:

• Cytosol
• Synaptic vesicles
• [Dendritic spines](/cell-types/dendritic-spines)
• Growth cones during development

Expression is particularly high in:

• Cortical pyramidal neurons
• Hippocampal CA1 pyramidal cells
• Cerebellar Purkinje cells
• Subventricular zone neural progenitors^[4]

Disease Associations

Epilepsy

Autosomal Dominant Focal Epilepsy (ADFE)

Heterozygous loss-of-function mutations in NPRL3 cause autosomal dominant focal epilepsy, typically manifesting in adolescence or early adulthood^[5]. Seizures often originate from the frontal or temporal lobes.

Developmental and Epileptic Encephalopathy (DEE)

Biallelic pathogenic variants can cause severe early-onset epileptic encephalopathy with developmental regression^[6].

References:

• PMID: 23471845(https://pubmed.ncbi.nlm.nih.gov/23471845/) - NPRL3 mutations cause focal epilepsy
• PMID: 32465690(https://pubmed.ncbi.nlm.nih.gov/32465690/) - Clinical features and genotype-phenotype correlations

Intellectual Disability

NPRL3 mutations are associated with:

• Global developmental delay
• Intellectual disability (mild to moderate)
• Speech impairment
• Behavioral problems including ADHD and autism features^[6]

Alzheimer's Disease

The [mTOR](/mechanisms/mtor-signaling-pathway) pathway is significantly dysregulated in Alzheimer's disease, and NPRL3 plays important roles:

• mTOR Hyperactivation: Reduced GATOR1 activity contributes to mTORC1 overactivation in AD brain
• [Autophagy](/entities/autophagy) Impairment: Defective GATOR1 function leads to impaired autophagy-lysosomal clearance of protein aggregates
• Synaptic Dysfunction: mTOR dysregulation affects synaptic plasticity and memory consolidation
• Amyloid-β Toxicity: NPRL3 dysfunction may exacerbate amyloid-induced neuronal damage

References:

• PMID: 25396082(https://pubmed.ncbi.nlm.nih.gov/25396082/) - mTOR signaling in Alzheimer's disease
• PMID: 26255403(https://pubmed.ncbi.nlm.nih.gov/26255403/) - Autophagy and neurodegeneration

Autism Spectrum Disorder

NPRL3 mutations are increasingly recognized in patients with autism spectrum disorder, particularly those with comorbid epilepsy. Shared molecular mechanisms involving mTOR dysregulation and synaptic dysfunction underlie both conditions^[7].

Parkinson's Disease

Emerging evidence suggests:

• mTOR pathway alterations in PD substantia nigra
• Potential role in [alpha-synuclein](/mechanisms/alpha-synuclein) aggregation
• Autophagy dysfunction in PD pathogenesis

Brain Tumors

GATOR1 complex genes, including NPRL3, function as tumor suppressors in the brain:

• Associated with hemimegalencephaly
• May play role in cortical dysplasia

Therapeutic Implications

mTOR Inhibitors

For epilepsy patients with NPRL3 mutations:

• Everolimus: mTOR inhibitor showing efficacy in reducing seizure frequency
• Sirolimus: Alternative mTOR inhibitor
• Dosing requires careful monitoring for adverse effects

Autophagy Modulators

Compounds that enhance autophagy may help clear protein aggregates:

• Rapamycin: Autophagy inducer (mTOR inhibitor)
• Metformin: AMPK activator promoting autophagy
• Natural compounds (resveratrol, curcumin) under investigation

Ketogenic Diet

Metabolic therapy may provide seizure control:

• Shifts brain metabolism to ketone bodies
• Reduces neuronal excitability
• May improve mitochondrial function

Antiseizure Drugs

Standard antiseizure medications remain first-line:

• Levetiracetam
• Valproic acid
• Carbamazepine
• Lacosamide

Selection should consider individual patient factors and seizure type.

Animal Models

Mouse Models

• Nprl3 knockout mice: Viable but show increased susceptibility to seizures
• Conditional knockouts: Brain-specific deletion leads to mTOR hyperactivation and seizures
• heterozygous mice: Exhibit mild cognitive deficits

Zebrafish Models

• Morpholino knockdown causes developmental abnormalities
• Seizure-like behavior observed
• Useful for high-throughput drug screening

GATOR1 Complex Assembly

Complex Structure

The GATOR1 complex is a heteromeric assembly with distinct subunit roles[nprla]:

Assembly Pathway

NPRL2 forms the central scaffold

NPRL3 binds to NPRL2 via coiled-coil domains

DEPDC5 associates as the catalytic subunit

Conformational Regulation

• Active state: Rag GTPase-bound, GAP activity high
• Inactive state: Complex dissociated or inhibited

Protein-Protein Interactions

Core Interactions

Regulatory Partners

Neurological Phenotypes

Seizure Mechanisms

The mechanistic basis for NPRL3-related epilepsy[depdc]:

mTORC1 hyperactivation: Disinhibited mTORC1 signaling

Protein synthesis dysregulation: Aberrant synaptic protein synthesis

Neuronal hyperexcitability: Altered ion channel expression

Network hypersynchrony: Excessive neuronal connectivity

Developmental Impact

NPRL3 mutations affect brain development:

• Dendritic arborization abnormalities
• Synapse formation defects
• Cortical layering disruptions
• Myelination abnormalities

Therapeutic Strategies

Current Approaches

Emerging Therapies

GATOR1 stabilizers: Small molecules promoting complex function

Gene therapy: AAV-mediated NPRL3 delivery

Antisense oligonucleotides: Variant-specific targeting

Combination Approaches

Rational combinations under investigation:

• mTOR inhibitor + ketogenic diet
• mTOR inhibitor + autophagy inducer
• Metabolic therapy + seizure medication

Neuropsychiatric Implications

Autism Spectrum Disorder

NPRL3 mutations in ASD[mtora]:

• Estimated 1-2% of ASD cases
• Comorbid with intellectual disability
• Seizures frequently present
• Response to mTOR inhibitors

Intellectual Disability

Mechanisms include:

• Synaptic dysfunction
• Altered protein synthesis
• Neural circuit abnormalities
• Developmental arrest

See Also

Precision Medicine: Developing gene-specific therapies for NPRL3-associated epilepsy

mTOR Pathway Modulation: Novel compounds targeting the GATOR1-mTOR axis

Biomarkers: Identifying biomarkers for early detection and treatment response

Structure-Function Studies: Understanding how NPRL3 mutations affect complex assembly and function

Neurodevelopmental Mechanisms: Elucidating the role in cortical development

Background

The study of Nprl3 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

See Also

• NPRL2 Gene - GATOR1 subunit partner
• DEPDC5 Gene - GATOR1 catalytic subunit
• GATOR Complex - Complex overview
• mTOR Pathway - Signaling pathway
• Epilepsy - Primary disease association
• [Alzheimer's Disease](/diseases/alzheimers-disease) Disease association
• Autism Spectrum D- [Parkinson's Disease](/diseases/parkinsons-disease)iation
• [Parkinson's Disease](/diseases/parkinsons-disease) Disease association

External Links

• [NCBI Gene NPRL3](https://www.ncbi.nlm.nih.gov/gene/84450)
• [UniProt Q9Y5Q3](https://www.uniprot.org/uniprotkb/Q9Y5Q3)
• [HGNC NPRL3](https://www.genenames.org/data/hgnc_data.php?hgnc_id=28669)
• [Ensembl NPRL3](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000177732)
• [ClinVar NPRL3](https://www.ncbi.nlm.nih.gov/clinvar/?term=NPRL3)
• [OMIM NPRL3](https://www.omim.org/entry/617052)

References

[Unknown, - NPRL3 mutations cause autosomal dominant focal epilepsy (n.d.)](https://pubmed.ncbi.nlm.nih.gov/23471845/)

[Unknown, - GATOR1 complex in epilepsy and neurodevelopment (n.d.)](https://pubmed.ncbi.nlm.nih.gov/32465690/)

[Unknown, - mTOR signaling in Alzheimer's disease pathogenesis (n.d.)](https://pubmed.ncbi.nlm.nih.gov/25396082/)

[Unknown, - Autophagy impairment in neurodegenerative diseases (n.d.)](https://pubmed.ncbi.nlm.nih.gov/26255403/)

[Unknown, - NPRL3 and brain development (n.d.)](https://pubmed.ncbi.nlm.nih.gov/28714933/)

[Unknown, - DEPDC5 and NPRL3 in epileptic encephalopathy (n.d.)](https://pubmed.ncbi.nlm.nih.gov/29873876/)

[Unknown, - mTOR dysregulation in autism spectrum disorder (n.d.)](https://pubmed.ncbi.nlm.nih.gov/31154289/)

GATOR1 Complex Assembly and Regulation

Complex Architecture

The GATOR1 complex is a heterotrimeric assembly with distinct structural domains[gator]:

The three subunits assemble through cooperative protein-protein interactions:

NPRL2 forms homodimers as the core scaffold

NPRL3 binds NPRL2 dimers through C-terminal coiled-coil domains

DEPDC5 associates via interactions with both NPRL2 and NPRL3

Regulatory Mechanisms

GATOR1 activity is tightly controlled through multiple mechanisms:

• Amino acid sensing: GATOR2 upstream activates GATOR1 during amino acid starvation
• Post-translational modifications: Phosphorylation affects complex activity
• Protein stability: Complex formation protects individual subunits from degradation
• Subcellular localization: Lysosomal recruitment determines functional output

Structural Insights

Cryo-EM studies have revealed:

• GATOR1 adopts an elongated structure approximately 150 Å in length
• The NPRL2-NPRL3 interface forms the central scaffold
• DEPDC5 sits at the periphery with its GAP domain accessible
• Rag GTPase binding induces conformational changes

Neurological Disease Pathogenesis

Epilepsy Mechanisms in Detail

NPRL3 mutations cause epilepsy through disruption of the GATOR1-mTOR axis[nprl]:

Molecular cascade:

Loss-of-function mutation reduces GATOR1 activity

Rag GTPases remain in active GTP-bound state

mTORC1 localizes to lysosomal surface and becomes activated

Increased protein synthesis promotes neuronal hyperexcitability

Seizure generation through cortical network hypersynchrony

Seizure semiology:

• Focal seizures with impaired awareness
• Often with auditory or autonomic features
• Secondary generalization in some cases
• Clusters common, especially during sleep

Alzheimer's Disease Connections

In Alzheimer's disease, NPRL3 dysfunction contributes to:

• Amyloid-β accumulation: Impaired autophagy fails to clear Aβ aggregates
• Tau pathology: mTOR hyperactivation affects tau phosphorylation and clearance
• Synaptic loss: Dysregulated protein synthesis disrupts synaptic homeostasis
• Neuronal death: Combined effects lead to progressive neurodegeneration

Parkinson's Disease Interactions

NPRL3 connections to Parkinson's disease:

• mTOR pathway alterations: Seen in PD substantia nigra
• Autophagy dysfunction: Affects alpha-synuclein clearance
• Lysosomal involvement: Links to GBA and other PD genes
• Dopaminergic vulnerability: Enhanced susceptibility to mTOR dysregulation

Autism Spectrum Disorder Mechanisms

ASD associated with NPRL3 mutations involves:

• Synaptic dysfunction: Altered local protein synthesis at synapses
• Circuit development: Abnormal neural connectivity during development
• Behavior: Social deficits, repetitive behaviors
• Comorbidities: Frequently associated with epilepsy

Therapeutic Approaches

mTOR Inhibitors

Autophagy Modulation

Alternative approaches to enhance protein clearance:

• Trehalose: 100 mM, mTOR-independent
• Metformin: 500-1000 mg/day, AMPK activation
• Resveratrol: 250-500 mg/day, SIRT1 activation
• Lithium: 300-900 mg/day, inositol depletion

Dietary Interventions

Ketogenic diet for NPRL3-related epilepsy:

• Classical KD: 3:1 or 4:1 ratio
• Modified Atkins: Less restrictive
• Low-glycemic index: Less strict, more sustainable

Gene Therapy Perspectives

Future directions include:

• AAV-NPRL3 delivery
• CRISPR-based allele editing
• Antisense oligonucleotides
• Protein replacement therapy

Research Model Systems

In Vitro Models

• Primary neurons: Cortical and hippocampal cultures
• iPSC neurons: Patient-derived disease modeling
• Brain organoids: 3D models for development
• Cell lines: HEK293, SH-SY5Y for mechanistic studies

In Vivo Models

• Nprl3 knockout mice: Viable but seizure-prone
• Conditional knockouts: Brain-specific deletion
• Zebrafish: Morpholino knockdown models

Experimental Techniques

• CRISPR/Cas9: Gene editing and mutation modeling
• Proteomics: Complex composition analysis
• Metabolomics: Metabolic pathway profiling
• Electrophysiology: Neuronal activity measurement
• Behavioral testing: Seizure and cognitive assessment

Clinical Management

Diagnosis and Testing

• Genetic testing: Panel or exome sequencing
• Interpretation: Pathogenic vs. VUS classification
• Family testing: Cascade screening

Long-term Management

• Neurological follow-up: Regular seizure assessment
• Cognitive monitoring: Developmental tracking
• Imaging: MRI for structural changes
• Quality of life: Psychosocial support

Multidisciplinary Care

Optimal care involves:

• Neurology
• Genetics
• Developmental pediatrics
• Psychology
• Dietary services

Summary

NPRL3 (NPR3-Like, GATOR1 Complex Subunit) encodes a critical component of the GATOR1 complex, which serves as the primary negative regulator of mTORC1 signaling in response to amino acid deprivation. NPRL3 functions as a regulatory subunit that stabilizes the GATOR1 complex and facilitates its proper function in amino acid sensing. Pathogenic variants in NPRL3 cause autosomal dominant focal epilepsy, and dysregulated mTOR signaling contributes to Alzheimer's disease, Parkinson's disease, autism spectrum disorder, and other neurodevelopmental and neurodegenerative conditions. The GATOR1-mTOR axis represents an important therapeutic target for these disorders, with mTOR inhibitors and autophagy modulators showing promise for treatment.

Pathway Diagram

The following diagram shows the key molecular relationships involving NPRL3 Gene discovered through SciDEX knowledge graph analysis: